We pioneered studies using low doses of PMZ-2010 (Centhaquine), which significantly reduced the mortality, decreased blood lactate, and increased mean arterial pressure, pulse pressure and cardiac output in hemorrhagic shock.
We have carried out comparative studies between PMZ-2010 (Centhaquine) and status quo resuscitative agents grouped into 3 different categories: (a) fluids such as Lactated Ringer’s, hypertonic saline; (b) adrenergic agents such as norepinephrine; and (c) fresh blood. Our results using (i) a rat model of fixed pressure blood loss, (ii) a rabbit model of uncontrolled bleeding with trauma, and (iii) a pig model of massive blood loss, indicate that PMZ-2010(Centhaquine) is highly effective in reducing the mortality following hypovolemic shock.
PMZ-2010 (Centhaquine) acts through a unique mechanism of action that is completely different from any of the existing drugs or investigational products. It is NOT a vasopressor, however, it increases blood pressure and cardiac output by augmenting venous blood return to the heart (alpha2B-adrenergic stimulation), and it enhances tissue perfusion by arterial dilatation (alpha1-adrenergic block). Enhancing tissue perfusion is a significant advantage in reducing the adverse effects of existing vasopressors. Moreover, it does not act on beta-adrenergic receptors, and therefore the risk of arrhythmias is mitigated.
Patents issued in Australia, Japan, India, China and European Union.
Clinical stage – Phase I (NCT02408731) completed; Phase II (NCT04056065) completed; Phase III (NCT04045327) completed; Marketing authorization received from Indian regulatory agency.
Hypovolemic Shock (PMZ-2010 (Centhaquine))